Oryginalne publikacje
Behringer, D., et al. (2021). „Planowanie leczenia z wyprzedzeniem – projekt praktyczny dotyczący wdrożenia planowania opieki z wyprzedzeniem w oddziale onkologicznym.” Czasopismo Medycyny Paliatywnej 22(05): 265-270.
Hüttmann A, et al. Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the „Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial. Ann Hematol. 2019 Jan 4. doi: 10.1007/s00277-018-3578-0. [Epub ahead of print] PubMed PMID: 30610279.
Braess J, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1. PubMed PMID: 30275528; PubMed Central PMCID: PMC6286323.
Knödler M et al. Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer. Br J Cancer. 2018 Aug;119(3):296-302. doi: 10.1038/s41416-018-0150-6. Epub 2018 Jul 10. PubMed PMID: 29988111
Dührsen U et al. PETAL Trial Investigators.. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11. PubMed PMID: 29750632.
Al-Batran SE, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22. PubMed PMID: 27776843.
Joerger M et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016 Oct;27(10):1895-902. doi: 10.1093/annonc/mdw290. Epub 2016 Aug 8. PubMed PMID: 27502710.
Schuette W, Behringer D, et al. CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status. Clin Lung Cancer. 2015 Nov;16(6):447-56. doi: 10.1016/j.cllc.2015.05.009. Epub 2015 Jun 2. PubMed PMID: 26094080.
Oza AM, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. PubMed PMID: 26115797; PubMed Central PMCID: PMC4648090.
10. Proetel U et al. Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol. 2014 Jul;93(7):1167-76. PubMed PMID: 24658964; PubMed Central PMCID: PMC4050299.
Dittrich C, et al. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer. 2014 Jun;50(9):1571-80. doi: 10.1016/j.ejca.2014.03.007. Epub 2014 Apr 2. PubMed PMID: 24703574.
Behringer D et al. Treatment approaches to primary tracheal cancer. Thorac Surg Clin. 2014 Feb;24(1):73-76. doi: 1016/j.thorsurg.2013.10.002. PubMed PMID: 24295662.
Stein A, Kretzschmar A, Behringer D et al. Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. BMC Cancer. 2013 Oct 4;13:454. doi:
1186/1471-2407-13-454. PubMed PMID: 24090011; PubMed Central PMCID: PMC3850951.
Sand M, et al. Gallbladder metastasis from renal cell carcinoma mimicking acute cholecystitis. Eur J Med Res. 2009;14:90-2. PubMed PMID: 19258219; PubMed Central PMCID: PMC3351966.
Gerstner ER, et al. CNS Hodgkin lymphoma. Blood. 2008 Sep 1;112(5):1658-61. doi: 10.1182/blood-2008-04-151563. Epub 2008 Jun 30. PubMed PMID: 18591379; PubMed Central PMCID: PMC3710443.
Gelos M, Behringer D et al. Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature. JOP. 2008 Jan 8;9(1):50-5. Review. PubMed PMID: 18182744.
Thomas-Kaskel AK et al. Reticulated platelet counts correlate with treatment response in patients with idiopathic thrombocytopenic purpura and help identify the complex causes of thrombocytopenia in patients after allogeneic hematopoietic stem cell transplantation. Cytometry B Clin Cytom. 2007 Jul;72(4):241-8. PubMed PMID: 17266149.
Heining C, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. Bone Marrow Transplant. 2007 May;39(10):613-22. Epub 2007 Mar 26. PubMed PMID: 17384658.
Sissung TM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006 Nov;42(17):2893-6. Epub 2006 Sep 6. PubMed PMID: 16950614; PubMed Central PMCID: PMC1647318.
Engelhardt M, Ihorst G, Behringer D, Finke J, Roth B. Incidence of monoclonal B-cell disease in siblings of patients with multiple myeloma. Haematologica. 2006 Feb;91(2):274-6. PubMed PMID: 16461322.
Mielke S, Sparreboom A, Behringer D, Mross K. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res. 2005 Nov-Dec;25(6C):4423-7. PubMed PMID: 16334120.
Chan S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005 Aug 10;23(23):5314-22. Epub 2005 Jun 13. PubMed PMID: 15955899.
Karthaus M, et al. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally adminiserterd bedesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 68(4-6):326-332, 2005
Mielke S, et al. Association of paclitaxwl pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin. Cancer Res. 11(13):4843-50, 2005
Mross K, et al. A phase I clinical and pharmacokinetic sstudy of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. Ann. Oncol. 15(8):1284-94, 2004
Spyridonidis A, et al. Reduced intensity conditioning compared to standard conditioning preserves the in vitro growth capacity of bone marrow stroma, which remains of host origin. Stem Cells Dev. 14(2):213-22, 2005
Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Monting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis – a single centre experience. Br J Haematol. 124(6):762-8, 2004
Spyridonidis A, Schmitt-Graff A, Tomann T, Dwenger A, Follo M, Behringer D, Finke J. Epithelial tissue chimerism after human hematopoietic cell transplantation is a real phenomenon. Am J Pathol. 164(4):1147-55, 2004
Roesler KW et al. Identification of beta-subunit of bacterial RNA-polymerase–a non-species-specific bacterial protein–as target of antibodies in primary biliary cirrhosis. Dig Dis Sci. 48(3):561-9, 2003
Burger JA, Spoo A, Dwenger A, Burger M, Behringer D. CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol. 122(4):579-89, 200
Mielke S, Mross K, Gerds TA, Schmidt A, Wasch R, Berger DP, Lange W, Behringer D. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs14(10):785-92, 2003
Lohr J, Mielke S, Lubbert M, Behringer D. Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. In Vivo17(5):505-7, 2003
Behringer B et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Annals of Hematology 82(7):381-9, 2003
K. Mross, B. et al. Comparison of the 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomised trial; Onkologie25:503-508, 2002
S. Klippel, et al. Biochemical Characterization of PRV-1, a Novel Hematopoietic Cell Surface Receptor, which is Overexpressed in Polycythemia Rubra Vera. Blood 100:2442-2448, 2002
Spyridonidis A, Fischer KG, Glocker FX, Fetscher S, Klisch J, Behringer D. Paraneoplastic cerebellar degeneration and nephrotic syndrome preceding Hodgkin´s disease: case report and review of the literature. European Journal of Haematology 68:318-321,2002
H. Gelderblom, K. Mross, A. ten Tije, D. Behringer, S. Mielke, D. van Zomeren, J. Verweij, A. Sparreboom. Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions. J Clin Oncol 20:574-581, 2002
M. Engelhardt, J. Douvillle, D. Behringer, A. Jähne, A. Smith, R. Mertelsmann, W. Lange: Use of ex vivo perfusion culture expanded bone marrow (BM) cells after myeloablative (STAMP V) Chemotherapy. Bone Marrow Transplantation, 27:249-259, 2001
D. Behringer, A. Spyridonidis, S. Fetscher, A. Schmitt-Gräff, S. Högerle & R. Kaiser: Paraneoplastic Polyneuropathy Preceding the Diagnosis of Hodgkin’s Disease and Non Small Cell Lung Cancer in a Patient with Concomitant Borrelia Burgdorferi Infection, Annals of Hematology 80: 232-235, 2001
Behringer D, Schaufler J, Kresin V, Lübbert M, Lindemann A: Differentiation Associated Modulation of the Cytokine and Chemokine Expression Pattern in Human Myeloid Cell Lines. Leukemia Research 25:141-149, 2001
Mathias Oelke, Toshiro Kurokawa, Iris Hentrich, Dirk Behringer, Vincenzo Cerundolo*, Albrecht Lindemann and Andreas Mackensen: Functional Characterization of CD8+ Antigen-Specific Cytotoxic T Lymphocytes after Enrichment Based on Cytokine Secretion: Comparison with the MHC-Tetramer Technology. Scand. J. Immunol. 52:544-549, 2000
Veelken H, Wasch R, Behringer D, Bertz H, Finke J. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning. Bone Marrow Transplant. 26(8):911-5, 2000
Finke J, Bertz, H, Schmoor C, Veelken H, Behringer D, Wäsch R, Kunzmann R, Heidecker L, Lang H, Meyer-König U, Mertelsmann R: Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. British Journal of Haematology 111:303-313, 2000
Ölke M, Möhrle U, Chen J, Behringer D, Lindemann A, Mackensen A: Generation and purification of CD8(+) Melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 6(5):1997-2005, 2000
Würthner J, Köhler G, Behringer D, Lübbert M: Leukostasis Followed by Hemorrhage Complicating the Initiation of Chemotherapy in Acute Myeloid Leukemia with Hyperleukocytosis. Cancer 85:368-74, 1999
Behringer D, H Bertz, C Schmoor*, C Berger, A Dwenger and J Finke. Lymphocyte Reconstitution after Allogeneic Hematopoietic Transplantation from Matched Related Donors: Comparison of CD34+ Selected PBPC Grafts with Unselected PBPC Grafts and BM Grafts. Bone Marrow Transplantation, 24, 295-302, 1999
Berger C, Bertz H, Schmoor C, Behringer D, Potthoff K, Mertelsmann R, Finke J: Influence of recombinant human granulocyte colony-stimulating factor (filgastrim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors. Bone Marrow Transplantation 23:983-990, 1999
Spyridonidis A, Bernhardt W, Behringer D, Azemar M, Pflug A, Mertelsmann R, Henschler R: Proliferation and Survival of Mammary Carcinoma Cells are Influenced by Culture conditions used for Ex Vivo-Expansion of CD34+ Blood Progenitor Cells. Blood 93:1-11, 1999
Lahn M, Fisch, P, Köhler G., Veelken H, Hentrich I, Behringer D, Muschal B, Kulmburg P, Iklé D, Lindemann A: Pro-inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma. European Urology, 35:70-80, 1999
Spyridonidis A, Bernhardt W, Fetscher S, Behringer D, Mertelsmann R, Henschler R: Minimal residual disease in autologous hematopoietic harvests from breast cancer patients. Annals of Oncology 9:821-826, 1998
Fetscher S, Lübbert M, Kanz L, Behringer D, Finke J, Mertelsmann R, Lange W: Treatment of Relapsed Non-Hodgkin’s Lymphoma after BEAM Chemotherapy and Autologous Transplantation by BU/CY Chemotherapy and Salvage Transplantation. Bone Marrow Transplantation 9:527-528, 1997
Behringer D, Kresin V, Henschler R, Mertelsmann R, Lindemann A: Cytokine and Chemokine Production by CD34+ Haemopoietic Progenitor Cells – Detection in Single Cells. British Journal of Haematology 97: 9-14, 1997
Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, Finke J: Interleukin-10 Increases bcl-2 Expression and Survival in Primary Human CD34+ Progenitor Cells. Blood 88:2549-2558, 1996
Waller CF, Bertz H, Wenger MK, Fetscher S, Hardung M, Engelhardt M, Behringer DM, Lange W, Mertelsmann R, Finke J: Mobilization of Peripheral Blood Progenitor Cells for Allogeneic Transplantation – Efficacy and Toxicity of a High-Dose RhG-CSF Regimen. Bone Marrow Transplantation 18:279-283, 1996
Vogel W, Behringer D, Scheding S, Kanz L, Brugger W: Ex vivo Expansion of CD34+ Peripheral Blood Progenitor Cells – Implications for the Expansion of Contaminating Epithelial Tumour Cells. Blood 8:2707-2713, 1996
Finke J, Brugger W, Bertz H, Behringer D, Kanz L, Mertelsmann R: Allogeneic Transplantation of Positively Selected Peripheral Blood CD34+ Progenitor Cells from Matched Related Donors. Bone Marrow Transplantation 18: 1081-1086, 1996
Behringer D, Sunderer B, Andersson U, Kresin V, Mertelsmann R, Lindemann A: Simultaneous Detection of Cytokine and Immunophenotype at the Single Cell Level by Immunoenzymatic Double Staining. Histochemical Journal 28:461-466, 1996
Behringer DM, Schaefer HE, Kunzmann R, Mertelsmann R, Dölken G. Translocation t(8q13q) in a Patient with T-Cell Lymphoma and Features of a Myeloproliferative Syndrome. Leukemia 9:988-992, 1995
Behringer DM, Meyer K-H, Veh RW: Antibodies against neuroactive amino acids and neuropeptides. II. Simultaneous immunoenzymatic double staining of neuroactive substances with labeled primary antibodies of one species and a combination of the ABC method and the hapten-antihapten-bridge (HAB) technique. J Histochem Cytochem 39:761-770, 1991
Meyer K-H, Behringer DM, Veh RW. Antibodies aginst neuroactive amino acids and neuropeptides. I. Development of an improved two step-procedure for glutaraladehyde based coupling of amino acids or peptides to carrier-proteins for immunization. J Histochem Cyto
Wkłady do książek
Behringer D, Engelhardt R: Mammakarzinom, S. 436-448. In „Das Rote Buch”, Edt: Berger D, Engelhardt R, Mertelsmann R; 2. Auflage:, 2002
Finke J, Bertz H, Veelken H, Behringer D, Kunzmann R, Wäsch R, Mertelsmann R: Fludarabine-Based Low Toxicity Conditioning for Allogeneic Peripheral Blood Stem Cell Tranplantation. In: Proceedings of the 4th International Stem Cell Workshop: High-Dose Therapy and Transplantation of Haematopoietic Stem Cells. Chairman and editor: Wolfgang Schulze, Bad Saarow; Blackwell-Wissenschafts-Verlag Berlin, Wien, 2000, S. 9-14
Behringer D, Lindemann A: Immunzytologie, „Das Rote Buch”, Edt: Berger D, Engelhardt R, Mertelsmann R, 2. Auflage:, 2002
Mertelsmann R, Engelhardt R, Behringer D, Berger D, Henß H (Editoren): Das Rote Buch gcp-m@nual. Ecomed Verlag, Landsberg, Lech, 2002, in Druck
Streszczenia (postery i prezentacje)
Veh RW, Behringer D, Andres K: Avidin-Biotin Based Sialic Acid Histochemistry. Verh. Anat. Ges. 78:115-116, 1984 (Vortrag)
Behringer D, Veh R: A New HAB-Technique – Trinitrophenylized Alkaline Phosphatase in Immunoenzymatic Staining of Haptenized Primary Antibodies. Anat. Anz. 161:122, 1986 (Posterbeitrag)
Veh R, Habbes H, Meyer K, Behringer D: Immunocytochemistry of Neuroactive Amino Acids- Evaluation of Specificities by Morphological Calibration of Immunologically Characterized Antibodies. Biol. Chem. H-S 369:1214, 1988 (Posterbeitrag)
Veh RW, Meyer KH, Behringer DM, Schätz CR, Petrasch E, Andres KH: Antibodies against Neuroactive Amino Acids and Neuropeptides. Combination of acetylcholinesterase cytochemistry with immunocytochemical double staining techniques for the demonstration of GABA and Glutamate like immunoreactivities in thalamus, hippocampus, cerebellar and cerebral cortex of the Rat. Acta histochemica, Suppl. Band 37, 189, 1989 (Posterbeitrag)
Behringer D, Aaron D, Veltri E: Outcome of Patients with Refractory Ventricular Tachyarrhythmia Declining Automatic Implantable Cardioverter-Defibrillator. J. Americ. Coll. Cardiol. 17 (Suppl. 2): 351A, 1991 (Vortrag)
Mackensen A, Veelken H, Behringer D, Lahn M, Rosenthal F, Kulmburg P, Wagner E, Mertelsmann R, Lindemann A: Receptor-mediated Interleukin-2 (IL-2) Gene Transfer into Human Renal Cell Carcinoma Cells. Onkologie 17 (Suppl.), 94, 1994 (Vortrag #373)
Behringer D, Kresin V, Veelken H, Mackensen A, Sunderer B, Mertelsmann R, Lindemann A: Simultaneous characterization of cytokine production and immunophenotype of human cells on the single cell level. Onkologie 17 (Suppl.), 8, 1994 (Posterbeitrag #29)
Lahn M, Köhler G, Behringer D, Kulmburg P, Veelken H, Rosenthal F, Mackensen A, Mertelsmann R, Lindemann A: Cytokine Secretion of Primary Cultures of Human Renal Cell Carcinomas. Onkologie 17 (Suppl.), 86, 1994 (Posterbeitrag #344)
Winkler J, Behringer D, Mertelsmann R, Brugger W, Kanz L: Immune reconstitution in patients after high-dose chemotherapy supported by positively selected CD34+ autologous peripheral blood progenitor cells. Bone Marrow Transplantation 15 (Suppl. 2), S40, 1995, (Posterbeitrag #184)
Waller C, Bertz H, Engelhardt M, Hardung M, Fetscher S, Behringer D, Lange W, Mertelsmann R, Finke J: Mobilization of peripheral blood progenitor cells (PBPC) for allogeneic peripheral blood progenitor cell transplantation (allo-PBPCT): efficacy and toxicity of a high dose rhG-CSF regimen. Bone Marrow Transplantation 17 (Suppl. 2), S71, 1995 (Posterbeitrag #24)
Weber-Nordt R, Behringer D, Schott E, Henschler R, Mertelsmann R, Finke J: IL-10 Rescues Bone Marrow and Blood Derived Human CD34+ Cells from Cell Death Induced by bcl-2 Deprivation. Blood 86 (Suppl. 1), 149a, 1995 (Posterbeitrag #585)
Finke J, Brugger W, Bertz H, Einsele H, Behringer D, Kanz L, Mertelsmann R: Allogeneic transplantation of peripheral blood derived CD34+ selected progenitor cells from matched related donors. Results of a clinical phase I/II study. Blood 86 (Suppl 1), 1995 (Vortrag #1148)
Spyridonidis A, Garbe A, Behringer D, Mertelsmann R, Henschler R: Transforming growth factor beta 1 inhibits growth of mammary carcinoma cells during ex vivo culture of CD34+ cells. Blood 88 (Suppl. 1), 250a, (Vortrag #433-II)
Behringer D, Bertz H, Hardung-Backes M, Winkler J, Engelhardt M, Mertelsmann R, Finke J: Allogeneic peripheral blood progenitor cell transplantation with or without CD34+ stem cell selection: follow up and immune reconstitution. Bone Marrow Transplantation 17 (Suppl. 1), S63, 1996 (Vortrag #298)
Behringer D, Kresin V, Henschler R, Mertelsmann R, Lindemann A: Cytokine Production by CD34+ Hematopoietic Progenitor Cells – Detection at the Single Cell Level. Annals of Hematology 73 (Suppl. 1-2), A68, 1996 (Posterbeitrag #269)
Bertz H, Burger J, Behringer D, Mertelsmann R, Finke J: Immunetherapy with Allogeneic Buffy Coats Cured Relapsed Multiple Myeloma after Allogeneic BMT. Bone Marrow Transplantation 17 (Suppl. 1), S69, 1996 (Posterbeitrag #320)
Finke J, Behringer D, Bertz H, Winkler J, Potthoff K, Hardung M, Berger C, Mertelsmann R: Allogeneic Peripheral Blood Stem Cell Transplantation with or without CD34+ Selection: Rapid Immune reconstiution and Low Incidence of GVHD. Annals of Hematology 73 (Suppl. 1-2), A165, 1996, (Beitrag #658)
Finke J, Behringer D, Bertz H, Berger C, Potthoff K, Winkler J, Hardung M, Mertelsmann R: Comparison of Immune Reconstitution and GvHD after Allogeneic Peipheral Blood Stem cell Transplantation with or without CD34+ Selection. Blood 88 (Suppl. 1), 616a (Vortrag #515-IV)
Spyridonidis A, Garbe A, Behringer D, Mertelsmann R, Henschler R: Use of transforming growth factor (TGF)-beta to inhibit growth of mammary carcinoma cells during ex vivo culture of CD34+ cells. Annals of Hematology 73 (Suppl. 1-2), A68, 1996 (Posterbeitrag #269)
Spyridonidis A, Garbe A, Behringer D, Mertelsmann R, Henschler R: Transforming Growth Factor (TGF)-beta 1 Inhibits Growth of Mammary Carcinoma Cells during ex Vivo Culture of CD34+ Cells. Blood 88 (Suppl. 1), 250a, 1996 (Vortrag #433-II)
Finke J, Bertz H, Behringer D, Heidecker E, Kunzmann R, Lang H, Potthoff K, Mertelsmann R: In Vivo Rabbit anti-T Lymphocyte Globulin Efficiently Avoids Severe GvHD after Allogeneic BMT from Matched or Mismatched Unrelated Donors. Bone Marrow Transplantation 19 (Suppl. 1), S186, 1997 (Posterbeitrag P742)
Behringer D, Schaufler J, Kresin V, Lindemann A: The Cytokine and Chemokine Pattern in Human Myeloid Cell Lines is Modulated by Induction of Differentiation. Onkologie 20 (suppl. 1), 64, 1997 (Posterbeitrag #234)
Bertz H, Afting M, Behringer D, Kunzmann R, Lang H, Potthoff K, Wäsch R, Mertelsmann R, Finke J: Pretransplant in Vivo T-Cell Depletion with Rabbit ATG Reduces the Incidence of Severe Graft-Versus-Host-Disease in Mismatched and Matched Unrelated Allogeneic Bone Marrow Transplantation. Onkologie 20 (suppl. 1), 15, 1997 (Vortrag #47)
Thomas A, Willebrand J, Lindemann A, Behringer D: Evaluation of Reticulated Platelets in Patients with Prolonged Thrombocytopenia: Onkologie 20 (suppl. 1), 290, 1997 (Posterbeitrag #290)
Spyridonidis A, Bernhardt W, Behringer D, Pflug A, Mertelsmann R, Henschler R: Proliferation and Survival of Mammary Carcinoma Cells are Influenced by Culture Conditions Used for ex Vivo Expansion of CD34+ Blood Progenitor Cells. Blood 90 (Suppl. 1), 422a, 1997 (Kongreßbeitrag #1873)
Spyridonidis A Bernhardt W, Behringer D, Pflug A, Mertelsmann R, Henschler R: Culture Conditions Used for Ex Vivo-Expansion of CD34+ Blood Progenitor Cells (BPC) Influence Survival and Proliferation of Mammary Carcinoma Cells. Onkologie 20 (suppl. 1), 90, 1997 (Posterbeitrag #336)
Spyridonidis A, Bernhardt W, Behringer D, Mertelsmann R, Henschler R: A Culture Step Substantially Enhances the Detection of Occult Tumor Cells in Bone Marrow of Breast Cancer Patients. Blood 90 (Suppl. 1), 215a, 1997 (Vortrag #409-II)
Berger C, Bertz H, Behringer D, Wäsch R, Afting M, Potthoff K, Mertelsmann R, Finke J: Hematopoietic Recovery After Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation. Onkologie 20 (suppl. 1), 144, 1997 (Posterbeitrag #553)
Finke J, Bertz H, Kunzmann R, Behringer D, Afting M, Heidecker E, Lang H, Potthoff K, Wäsch R, Mertelsmann R: Allogeneic transplantation from Unrelated Donors: Improved Outcome Using in Vivo T Cell Depletion. Blood 90 (Suppl. 1), 103a, 1997 (Kongreßbeitrag #451-I)
Behringer D, Engelhardt M, Schmoor C, Bertz H, Lohr J, Finke J: Role of CD34+ Determination in Allogeneic Peripheral Blood (PB) and Bone Marrow (BM) Grafts for Hematologic and Clinical Outcome. Annals of Haematology 77 (suppl II), S79, 1998 (Posterbeitrag #312)
Behringer D, Bertz H, Finke J: Comparable Lymphocyte Reconstitution after Transplantation from Matched Related Donors with CD34+ Selected Peripheral Blood Progenitor Cell (PBPC) Grafts or Unseleceted PBPC Grafts. Annals of Haematology 77 (suppl II), S79, 1998 (Posterbeitrag #311)
Finke J, Bertz H, Afting M, Behringer D, Berger C, Heidecker L, Kunzmann R, Marks R, Potthoff K Wäschr R, Winkler J, Mertelsmann R: Allogeneic Transplantation of CD34+ Selected of Unselected Peripheral Blood Progenitor Cells. Bone Marrow Transplantation 22 (Suppl. 2), S8, 1998 (Kongreßbeitrag #SP13)
Engelhardt M, Henschler R, Kalle C, Behringer D, Stockschläder M, Finke J, Schulz G, Mertelsmann R, Lange W: Transplantation of ex vivo Perfusion Culture Expanded Bone Marrow Cells Produces Durable Hematopoietic Reconstitution after Myeloablative Chemtoherapy. Annals of Haematology 77 (suppl II), S29, 1998 (Vortrag #111)
Engelhardt M, Douville J, de Reys S, von Kalle C, Behringer D, Schulz G, Armstrong D, Mertelsmann R, Lange W: Transplantation of ex Vivo Perfusion Culture Expanded Bone Marrow Cells Produces Durable Hematopoietic Reconstitution after Myeloablative Chemotherapy. Blood 92 (Suppl. 1), 126a, 1998 (Posterbeitrag #509)
Würthner J, Behringer D, Köhler G, Daskalakis M, Mertelsmann R, Lindemann A, Lübbert M: Leukostasis Followed by Lethal Cerebral Hemorrhage – a Complication of Acut
Myelomonocytic Leukemia with Hyperleukocytosis. Blood 92 (Suppl. 1), 214b, 1998 (Kongreßbeitrag #3920)
Spyridonidis A, Bernhardt W, Azemar M, Behringer D, Pflug A, Wels W, Groner B, Henschler R: Purging of Mammary Carcinoma Cells During CD34+ Expansion Culture. Annals of Haematology 77 (suppl II), S210, 1998 (Posterbeitrag #834)
Engelhardt M, Douville J, von Kalle C, Behringer D, Armstrong D, Mertelsmann R, Lange W: Update on the use of ex vivo perfusion culture expanded bone marrow (BM) cells after myeloablative chemotherapy. Onkologie 22 (suppl 1), 27, 1999 (Posterbeitrag #74)
Behringer D, Bauer D, Henschler R, Lindemann A: M-CSF is Secreted by CD34+ Hematopoietic Progenitor Cells (CD34+HPC) During ex Vivo Expansion and during Culture on Bone Marrow Stroma. Onkologie 22 (suppl 1), 178, 1999 (Vortrag #680)
Finke J, Bertz H, Veelken H, Wäsch R, Behringer D, Illerhaus G, v. Kalle C, Kunzmann R, Lang H, Schwabe M, Mertelsmann R: In vivo T Cell Depletion with ATG Reduces GvHD in Unrelated Donor Stem Cell Transplantation. Blood 94 (Suppl. 1), 713A, (Abstract 3148, Kongreßvortrag), 1999
Finke, J., H. Bertz, et al., …. D. Behringer. „Fludarabine based low toxicity conditioning for allogeneic PBSCT.” Bone Marrow Transplantation 23: S3c (1999)
Wäsch R, Sauer B, Behringer D, Engelhardt M, Bertz H, Finke J: Donor Origin of Bone Marrow Stromal Cells after Allogeneic Stem Cell Transplantation. Blood 94 (10, Suppl. 1), #166 (Posterbeitrag ASH), 1999
Mielke S, Behringer D, Henss H, Lindemann A: Response and survival in eleven patients with advanced gastric cancer treated with the PELV regimen. J Cancer Res Clin Oncol 126 (Suppl) R111; Abstract S0235 P-33, 2000
Behringer D, Mielke S, Bertz H, Dwenger A, Burger J, Finke J: Lymphocyte Reconstitution after BMT from unrelated Donors and in vivo T-cell depletion with anti-Thymocyte Globulin. Onkologie 23 (Sonderheft 7) 122; #460, 2000
B. Behringer, R. Kunzmann, C. Schmoor, D. Behringer, R. Mertelsmann, M. Lübbert: Serum lactate dehydrogenase (LDH) as an independent prognostic factor for overall survival in patients with acute myeloid leukemia (AML) aged >55 years. Blood 96 (11 Part 1): 123a, Abstract #531 (Posterbeitrag ASH), 2000
Jan A. Burger, Bingrong Zhou, Anne Dwenger, Dirk Behringer: Spontaneous migration of CD34+ progenitor cells beneath marrow stromal cells (pseudoemperipolesis) requires VLA-4 integrins and the CXCR4 chemokine receptor and differentially affects cell cycle progression in CD34+ progenitor cells or CD34+ myeloid leukemia cells. Blood 96 (11 Part 1): 688a, Abstract #2961 (Posterbeitrag ASH), 2000
D. Behringer, S. Mielke, H. Bertz, J. Finke: Effects of ATG Dosage on T-Lymphocyte Reconstitution after unrelated donro bone marrow transplantation. Blood 96 (11 Part 2): 359b, Abstract #5307 (ASH), 2000
Oelke, M., A. Tuczek, …, D. Behringer, W. Kreisel. „Specific Th-2-type reaction of T-lymphocytes of PBC patients to calreticulin and bacterial RNA-polymerase.” Gastroenterology 120(5): 1825. (Posterbeitrag, AGA Atlanta, 2001)
Burger, J. A., A. Burkle, D. Behringer. „B cell chronic lymphocytic leukemia cells express functional CXCR5 chemokine receptors for the chemokine B cell-activating chemokine-1 (BCA-1/CXCL13).” Blood 98(11): 639, (Posterbeitrag, ASH, 2001).
Spyridonidis, A., T. Tomann, …, D. Behringer, J. Finke. „Chimeric status of gut epithelium after human hematopoietic stem cell
transplantation (HSCT).” Blood 98(11): 3288, (Vortrag, ASH, 2001)
Bertz, H., D. Behringer, K. Potthoff, J. Finke: „Allotransplantation from unrelated and related donors in patients with active disease in the seventh decade of life.” Bone Marrow Transplantation 27: S84-S84, (Posterbeitrag, EBMT, 2001)
K. Mross, B. Niemann, C.Unger, D., N. Holländer, M. Schumacher, S. Mielke, D. Behringer. Comparison of the pharmakokinetics of a 1-hour and a 3-hour paclitaxel infusion – results of a randomized study. Journal of Clinical Oncology 20 (Part 1): 107a (#424; ASCO 2001) Posterbeitrag)
Stephan Mielke, Klaus Mross Franz-Xaver Glocker, Clemens Unger, Dirk Behringer: Neurotoxicity of paclitaxel infused weekly over one versus three hours: preliminary results of a phase III trial. Journal of Clinical Oncology 20 (Part 1): 107a (#425; ASCO 2001 Posterbeitrag)
C. Dittrich, J. Beck, D. Behringer, C. Bokemeyer, M. Borner, M. De Santis, H. Fiebig, G. Gastl, R. Hofheinz, D. Hossfeld, H. Illiger, R. Morant, K. Mross, W. Queißer, D. Reichert, M. Scheulen, J. Schüller, J. von Pawel: Central European Society for Anticancer Drug Research-EWIV: Phase I- and II- studies. Onkologie 26 (Sonderheft 6):9, 2001
Spyridonidis A, Dwenger A, Tomann T, Follo M, Behringer D, Finke J: Chimeric Status of gut epithelium after human bone marrow transplantation. Onkologie 24 (Sonderheft 6):12 (Abstract #44); 2002
Burger J, Birkle A, Behringer D. B cell chronic lymphocytic leukemia cells express functional CXCR5 chemokine receptors for the chemokine B cell-activating chemokin-1 (BCA-1). Onkologie 24 (Sonderheft 6):76 (Abstract #291); 2002
Bertz H, Potthoff K, Behringer D, Finke J: Successful allotransplantation from unrelated and related donors in patients >60 years of age with active myeloid malignancies. Onkologie 24 (Sonderheft 6):121 (Abstract #459); 2002
Engelhardt M, Wider D, Samek E, Bertz H, Behringer D, Lübbert M: Selection of peripheral blood CD34+ cells using the immunomagnetic (Clinimacs) selection device for autologous and allogeneic transplantation. Onkologie 24 (Sonderheft 6):161 (Abstract #621); 2002
Behringer B, Kunzmann R, Schmoor C, Behringer D, Lübbert M: Single-center retrospective analysis of outcome and prognostic factors in 139 patients aged >55 years with acute myeloid leukemia (AML). Onkologie 24 (Sonderheft 6):194 (Abstract #747); 2002
Bernhardt W, Herling M, Behrens M, Jüttner E, Henß H, Behringer D: Quality assurance of chemotherapy by use of a central control system. Onkologie 24 (Sonderheft 6):222 (Abstract #858); 2002
Zgłoszone publikacje
Spyridonidis A, Behringer D, Henschler R: Bone marrow transplantation in breast cancer: should we purge? Lessons from the solid organ transplantation field. Submitted to Bone Marrow Transplantation, nie kontynuowano
A. Thomas, J. Willebrand, D. Mattern*, G. Köhler*, J. Finke, A. Lindemann & D. BehringerThe Diagnostic Impact of Reticulated Platelet Counts in Thrombocytopenic Patients with Idiopathic Thrombocytopenic Purpura or After Allogeneic Hematopoietic Stem Cell Transplantation; Europ. J. Haematology, 04/01 odrzucono, nie kontynuowano
Ölke M, Tuczek A, Behringer D, Männle H, Jensen D, Rössler K-W, Kreisel W: Th-2 Reaktion peripherer T-Lymphzyten auf Calreticulin und bakterielle RNA-Polymerase bei Primär biliärer Zirrhose. Eingereicht zur 56. Tagung der deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, 2001
Rössler K-W , W. Schmieder, G. Kurz, M. Kist, S. Batsford, E. Schiltz, M. Ölke, A. Tuuczek, T. Dettenborn, D. Behringer, W. Kreisel. Antikörper gegen die ß-Untereinheit der bakteriellen RNA-Polymerase bei der Primär Biliären Zirrhose (PBC); Eingereicht zur 56. Tagung der deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, 2001
K Mross, U Sauer, B Häring, D Behringer, E. Brendel, C Unger: A phase I dose escalation Pharmakokinetic (PK) Study of BAY 38-3441 administered as a short infusion once every three weeks. 04/01 submitted to ECCO
Phase I Dose Escalation Study on the Tolerability and Activity of BBR 3438 in Patients with Advanced Solid Tumors D.
Behringer1, R. Engelhardt1, R. Hofheinz2, A. Hochhaus2, R. Herrmann3, A. Stern4, G. Camboni5, A. Bernareggi5, accepted by ESMO 2002
J Lohr, S Mielke, M Lübbert, D Behringer: Fatal outcome in a patient with metastatic prostate cancer and acquired severe hypogammaglobulinemia with complete absence of mature peripheral blood B-cells. submitted Clin Lab Haematol
B. Roth, H. Bertz, J. Finke, D. Behringer.
This post is also available in:
